Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in […]
Category: News
First patient dosed in phase 1b/2a study of procizumab
Irish biotech’s germ-free egg platform could help close global shortfall
GlueSEEKER enables rational design of targeted protein degraders
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress
Funding to accelerate development of AI-driven tumour profiling tool OneMap
Healthinote rollout aims to improve early detection and patient self-management